Tetra is committed to building a leading portfolio of clinical trial stage treatments, based on phosphodiesterase sub-type inhibitors for both neuroscience and non-neuroscience disorders. These are fields in which we believe Tetra is poised to deliver multiple novel treatments, with the potential to change patients’ lives.
38 Fulton St W Ste 303 Grand Rapids, MI 49503
CEO: Dr. Mike E. Gurney PHD, MBA
VP: Mr. Richard M. Erwin